Cessatech A/S (FRA:8GN)

Market Cap	48.24M +86.1%
Revenue (ttm)	-615.78K
Net Income	-2.32M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Average Volume	n/a
Open	2.420
Previous Close	2.300
Day's Range	2.390 - 2.475
52-Week Range	0.775 - 3.345
Beta	n/a
RSI	47.68
Earnings Date	Feb 27, 2026

About Cessatech

Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8GN

Financial Performance

Financial numbers in DKK